Your browser doesn't support javascript.
loading
Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases.
Ezhov, Marat V; Shalnova, Svetlana A; Yarovaya, Elena B; Kutsenko, Vladimir A; Evstifeeva, Svetlana E; Metelskaya, Victoria A; Drapkina, Oxana M; Boytsov, Sergey A.
Afiliación
  • Ezhov MV; National Medical Research Center of Cardiology, Moscow, Russia.
  • Shalnova SA; National Medical Research Center of Therapy and Preventive Medicine, Moscow, Russia.
  • Yarovaya EB; Lomonosov Moscow State University, Moscow, Russia.
  • Kutsenko VA; Lomonosov Moscow State University, Moscow, Russia.
  • Evstifeeva SE; National Medical Research Center of Therapy and Preventive Medicine, Moscow, Russia.
  • Metelskaya VA; National Medical Research Center of Therapy and Preventive Medicine, Moscow, Russia.
  • Drapkina OM; National Medical Research Center of Therapy and Preventive Medicine, Moscow, Russia.
  • Boytsov SA; National Medical Research Center of Cardiology, Moscow, Russia.
Arch Med Sci ; 19(4): 995-1002, 2023.
Article en En | MEDLINE | ID: mdl-37560742
Introduction: Lipoprotein(a) (Lp(a)) is recognized as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to estimate the distribution of Lp(a) levels in working age adults from the Russian population and to assess its association with ischemic heart disease (IHD), myocardial infarction (MI), stroke, diabetes mellitus (DM), and arterial hypertension (AH). Material and methods: This substudy of the population-based study "Epidemiology of Cardiovascular Diseases and their Risk Factors in Some Regions of the Russian Federation" (ESSE-RF) included 8461 subjects aged 25-64 years (63.7% women) without lipid-lowering drugs. Atherosclerotic cardiovascular disease was self-reported. Lp(a), apolipoproteins AI and B, and lipid and glucose levels in blood serum were determined. Results: The prevalence of Lp(a) ≥ 30 mg/dl was 20.5% and 23.0%, and prevalence of Lp(a) ≥ 50 mg/dl was 13.3% and 15.2%, in men and women, respectively. An association of Lp(a) with IHD, MI, and AH, but not with stroke and DM, was shown. A cut-off level of Lp(a) of 9 mg/dl was determined, above which there was increased frequency of MI (by 59.2%, p = 0.02), IHD (by 33.4%, p < 0.001), and AH (by 11.6%, p < 0.001). In the multivariate analysis only the association of Lp(a) with IHD (1.19 (1.01-1.41), p = 0.038) and MI (1.57 (1.06-2.38), p = 0.028) remained significant. Conclusions: Lipoprotein(a) level ≥ 30 mg/dl was detected in every fifth adult aged 25-64 years. Increased risk of MI and IHD starts at an Lp(a) serum level above 9 mg/dl.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Arch Med Sci Año: 2023 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Polonia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Arch Med Sci Año: 2023 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Polonia